Janney Capital Management LLC Has $481,000 Stake in Exelixis, Inc. $EXEL

Janney Capital Management LLC reduced its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 11.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,910 shares of the biotechnology company’s stock after selling 1,429 shares during the quarter. Janney Capital Management LLC’s holdings in Exelixis were worth $481,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of EXEL. GAMMA Investing LLC boosted its stake in Exelixis by 4,779.4% in the first quarter. GAMMA Investing LLC now owns 201,472 shares of the biotechnology company’s stock worth $7,438,000 after purchasing an additional 197,343 shares in the last quarter. Merit Financial Group LLC raised its holdings in shares of Exelixis by 154.8% in the first quarter. Merit Financial Group LLC now owns 33,453 shares of the biotechnology company’s stock valued at $1,235,000 after buying an additional 20,325 shares during the last quarter. Sivia Capital Partners LLC lifted its position in Exelixis by 22.9% during the 1st quarter. Sivia Capital Partners LLC now owns 11,598 shares of the biotechnology company’s stock worth $428,000 after buying an additional 2,162 shares in the last quarter. UMB Bank n.a. lifted its position in Exelixis by 113.0% during the 1st quarter. UMB Bank n.a. now owns 2,899 shares of the biotechnology company’s stock worth $107,000 after buying an additional 1,538 shares in the last quarter. Finally, Park Avenue Securities LLC grew its holdings in Exelixis by 10.6% during the 1st quarter. Park Avenue Securities LLC now owns 7,358 shares of the biotechnology company’s stock worth $272,000 after acquiring an additional 707 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

EXEL has been the topic of several research analyst reports. Wall Street Zen cut shares of Exelixis from a “buy” rating to a “hold” rating in a research note on Monday, September 15th. JMP Securities reissued a “market outperform” rating and issued a $50.00 target price on shares of Exelixis in a research note on Tuesday, July 29th. Stephens upgraded Exelixis from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $29.00 to $60.00 in a research report on Tuesday, June 24th. UBS Group set a $38.00 price target on Exelixis and gave the company a “neutral” rating in a report on Wednesday, July 30th. Finally, Jefferies Financial Group set a $50.00 price objective on Exelixis and gave the stock a “buy” rating in a report on Tuesday, June 24th. Fourteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.42.

Exelixis Trading Up 1.8%

NASDAQ EXEL opened at $41.30 on Wednesday. Exelixis, Inc. has a 12 month low of $25.17 and a 12 month high of $49.62. The stock has a 50-day simple moving average of $38.83 and a 200 day simple moving average of $39.79. The company has a market capitalization of $11.12 billion, a PE ratio of 19.86, a P/E/G ratio of 0.84 and a beta of 0.32.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.63 by $0.12. The firm had revenue of $568.26 million for the quarter, compared to analysts’ expectations of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The company’s revenue was down 10.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.